Modernizing the World Health Organization List of Essential Medicines for Preventing and Controlling Cardiovascular Diseases

Sandeep P. Kishore; Evan Blank; David J. Heller; Amisha Patel; Alexander Peters; Matthew Price; Mahesh Vidula; Valentin Fuster; Oyere Onuma; Mark D. Huffman; Rajesh Vedanthan

doi:10.1016/j.jacc.2017.11.056

Modernizing the World Health Organization List of Essential Medicines for Preventing and Controlling Cardiovascular Diseases

Sandeep P. Kishore, Evan Blank, David J. Heller, Amisha Patel, Alexander Peters, Matthew Price, Mahesh Vidula, Valentin Fuster, Oyere Onuma, Mark D. Huffman, Rajesh Vedanthan

Research output: Contribution to journal › Review article › peer-review

40 Scopus citations

Abstract

The World Health Organization (WHO) Model List of Essential Medicines (EML) is a key tool for improving global access to medicines for all conditions, including cardiovascular diseases (CVDs). The WHO EML is used by member states to determine their national essential medicine lists and policies and to guide procurement of medicines in the public sector. Here, we describe our efforts to modernize the EML for global CVD prevention and control. We review the recent history of applications to add, delete, and change indications for CVD medicines, with the aim of aligning the list with contemporary clinical practice guidelines. We have identified 4 issues that affect decisions for the EML and may strengthen future applications: 1) cost and cost-effectiveness; 2) presence in clinical practice guidelines; 3) feedback loops; and 4) community engagement. We share our lessons to stimulate others in the global CVD community to embark on similar efforts.

Original language	English
Pages (from-to)	564-574
Number of pages	11
Journal	Journal of the American College of Cardiology
Volume	71
Issue number	5
DOIs	https://doi.org/10.1016/j.jacc.2017.11.056
State	Published - Feb 6 2018

Keywords

NCDs
WHO Essential Medicines List
cardiovascular disease
essential medicines

Access to Document

10.1016/j.jacc.2017.11.056

Cite this

Kishore, S. P., Blank, E., Heller, D. J., Patel, A., Peters, A., Price, M., Vidula, M., Fuster, V., Onuma, O., Huffman, M. D., & Vedanthan, R. (2018). Modernizing the World Health Organization List of Essential Medicines for Preventing and Controlling Cardiovascular Diseases. Journal of the American College of Cardiology, 71(5), 564-574. https://doi.org/10.1016/j.jacc.2017.11.056

@article{2bea0c50d62147a1a16c36794a98c278,

title = "Modernizing the World Health Organization List of Essential Medicines for Preventing and Controlling Cardiovascular Diseases",

abstract = "The World Health Organization (WHO) Model List of Essential Medicines (EML) is a key tool for improving global access to medicines for all conditions, including cardiovascular diseases (CVDs). The WHO EML is used by member states to determine their national essential medicine lists and policies and to guide procurement of medicines in the public sector. Here, we describe our efforts to modernize the EML for global CVD prevention and control. We review the recent history of applications to add, delete, and change indications for CVD medicines, with the aim of aligning the list with contemporary clinical practice guidelines. We have identified 4 issues that affect decisions for the EML and may strengthen future applications: 1) cost and cost-effectiveness; 2) presence in clinical practice guidelines; 3) feedback loops; and 4) community engagement. We share our lessons to stimulate others in the global CVD community to embark on similar efforts.",

keywords = "NCDs, WHO Essential Medicines List, cardiovascular disease, essential medicines",

author = "Kishore, {Sandeep P.} and Evan Blank and Heller, {David J.} and Amisha Patel and Alexander Peters and Matthew Price and Mahesh Vidula and Valentin Fuster and Oyere Onuma and Huffman, {Mark D.} and Rajesh Vedanthan",

note = "Publisher Copyright: {\textcopyright} 2018 American College of Cardiology Foundation",

year = "2018",

month = feb,

day = "6",

doi = "10.1016/j.jacc.2017.11.056",

language = "English",

volume = "71",

pages = "564--574",

journal = "Journal of the American College of Cardiology",

issn = "0735-1097",

number = "5",

}

Kishore, SP, Blank, E, Heller, DJ, Patel, A, Peters, A, Price, M, Vidula, M, Fuster, V, Onuma, O, Huffman, MD & Vedanthan, R 2018, 'Modernizing the World Health Organization List of Essential Medicines for Preventing and Controlling Cardiovascular Diseases', Journal of the American College of Cardiology, vol. 71, no. 5, pp. 564-574. https://doi.org/10.1016/j.jacc.2017.11.056

TY - JOUR

T1 - Modernizing the World Health Organization List of Essential Medicines for Preventing and Controlling Cardiovascular Diseases

AU - Kishore, Sandeep P.

AU - Blank, Evan

AU - Heller, David J.

AU - Patel, Amisha

AU - Peters, Alexander

AU - Price, Matthew

AU - Vidula, Mahesh

AU - Fuster, Valentin

AU - Onuma, Oyere

AU - Huffman, Mark D.

AU - Vedanthan, Rajesh

PY - 2018/2/6

Y1 - 2018/2/6

N2 - The World Health Organization (WHO) Model List of Essential Medicines (EML) is a key tool for improving global access to medicines for all conditions, including cardiovascular diseases (CVDs). The WHO EML is used by member states to determine their national essential medicine lists and policies and to guide procurement of medicines in the public sector. Here, we describe our efforts to modernize the EML for global CVD prevention and control. We review the recent history of applications to add, delete, and change indications for CVD medicines, with the aim of aligning the list with contemporary clinical practice guidelines. We have identified 4 issues that affect decisions for the EML and may strengthen future applications: 1) cost and cost-effectiveness; 2) presence in clinical practice guidelines; 3) feedback loops; and 4) community engagement. We share our lessons to stimulate others in the global CVD community to embark on similar efforts.

AB - The World Health Organization (WHO) Model List of Essential Medicines (EML) is a key tool for improving global access to medicines for all conditions, including cardiovascular diseases (CVDs). The WHO EML is used by member states to determine their national essential medicine lists and policies and to guide procurement of medicines in the public sector. Here, we describe our efforts to modernize the EML for global CVD prevention and control. We review the recent history of applications to add, delete, and change indications for CVD medicines, with the aim of aligning the list with contemporary clinical practice guidelines. We have identified 4 issues that affect decisions for the EML and may strengthen future applications: 1) cost and cost-effectiveness; 2) presence in clinical practice guidelines; 3) feedback loops; and 4) community engagement. We share our lessons to stimulate others in the global CVD community to embark on similar efforts.

KW - NCDs

KW - WHO Essential Medicines List

KW - cardiovascular disease

KW - essential medicines

UR - http://www.scopus.com/inward/record.url?scp=85044870466&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2017.11.056

DO - 10.1016/j.jacc.2017.11.056

M3 - Review article

C2 - 29406862

AN - SCOPUS:85044870466

SN - 0735-1097

VL - 71

SP - 564

EP - 574

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

IS - 5

ER -

Modernizing the World Health Organization List of Essential Medicines for Preventing and Controlling Cardiovascular Diseases

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this